Welcome to our dedicated page for CG Oncology SEC filings (Ticker: CGON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CG Oncology, Inc. (NASDAQ: CGON) SEC filings page provides access to the company’s official U.S. Securities and Exchange Commission disclosures related to its late-stage clinical biopharmaceutical activities in non-muscle invasive bladder cancer (NMIBC). As a public company, CG Oncology files periodic and current reports that describe its financial condition, governance changes, and key clinical and regulatory milestones for its investigational intravesical oncolytic immunotherapy, cretostimogene grenadenorepvec.
Among the most relevant documents for CGON are current reports on Form 8-K, which the company uses to report material events. Recent 8-K filings have detailed board of director changes, including the appointment of a new director and the resignation of another, as well as transitions in the principal financial and accounting officer role. Other 8-Ks reference press releases announcing quarterly financial results, updated BOND-003 Cohort C data in high-risk BCG-unresponsive NMIBC, and corporate presentations at healthcare conferences.
Investors also look to CG Oncology’s quarterly and annual reports (Forms 10-Q and 10-K, when available) for broader context on its clinical development program, including the BOND-003 and PIVOT-006 Phase 3 trials and the CORE-008 Phase 2 study, as well as information about its Expanded Access Program in North America. These filings typically discuss risk factors, research and development expenses, and other elements that shape the company’s outlook as a late-stage clinical biopharmaceutical issuer.
On Stock Titan, CGON filings are updated as they are posted to EDGAR, and AI-powered tools can help summarize lengthy documents such as earnings-related 8-K exhibits or future 10-K and 10-Q reports. Users can also review governance and compensation disclosures embedded in 8-K items related to director appointments and executive transitions, and track how these developments align with CG Oncology’s efforts to advance cretostimogene through the regulatory process.
CG Oncology, Inc. Chief Executive Officer Arthur Kuan exercised employee stock options and increased his direct ownership. On March 4, 2026, he exercised options for 102,871 shares of common stock at $1.72 per share, receiving 100,000 shares after a net exercise in which the company withheld 2,871 shares and he paid the remaining exercise price in cash. A related disposition of 2,871 shares at $61.61 per share was recorded for payment of the exercise price or tax liability and, as noted, does not represent an open-market sale. Following these transactions, Kuan directly owned 136,151 shares of CG Oncology common stock.
CG Oncology, Inc. is a late-stage biopharmaceutical company focused on cretostimogene grenadenorepvec, an oncolytic immunotherapy for bladder cancer. The drug is designed to selectively kill tumor cells and trigger an immune response through intravesical delivery, similar to BCG.
The lead program targets high-risk BCG-unresponsive non-muscle invasive bladder cancer, where Phase 3 BOND-003 Cohort C showed a 75.5% complete response rate at any time and durable responses out to 24 months, supporting a Biologics License Application initiated in late 2025. Additional Phase 3 and Phase 2 trials extend into intermediate-risk, BCG-naïve and BCG-exposed disease, and muscle-invasive settings.
The company is building a U.S. commercial organization, relies on third-party manufacturing including majority-owned Biovire, and holds regional partnerships with Kissei and Lepu. Intellectual property consists of multiple issued patents and applications covering cretostimogene use and combinations, with expected expiries into the late 2030s and 2040s.
CG Oncology, Inc. reported 2025 results showing it remains a late-stage, development-focused bladder cancer company investing heavily in cretostimogene. For 2025, total revenues were
Research and development expenses rose to
The company highlighted upcoming milestones for cretostimogene, including Phase 3 topline data from the PIVOT-006 trial in intermediate-risk NMIBC and Phase 2 first results from CORE-008 Cohort CX in high-risk NMIBC, both expected in the first half of
CG Oncology, Inc. filed an amendment to its prospectus to increase its at-the-market common stock offering under a sales agreement with Jefferies LLC to an aggregate offering price of up to $550,000,000. The amendment updates a prior prospectus that covered up to $250,000,000 of common stock under the same agreement. CG Oncology has already sold 5,861,984 shares for gross proceeds of $250,000,000 under this program, and the amendment adds up to an additional $300,000,000 of common stock capacity.
CG Oncology is updating its at-the-market equity program so it may sell up to $550.0 million of common stock through Jefferies under an existing sales agreement. The company has already sold 5,861,984 shares for gross proceeds of $250.0 million and is increasing the capacity by an additional $300.0 million. At a recent share price of $53.72, the amendment illustrates sales of 10,238,273 shares to raise about $550.0 million, which would raise net tangible book value per share from $8.60 to $13.62 as of September 30, 2025. New investors buying at that assumed price would face immediate dilution of $40.10 per share, and future option exercises or additional equity financings could further dilute existing holders.
CG Oncology director James Mulay reported option exercises and share sales for CG Oncology, Inc. common stock on January 9, 2026. He exercised a director stock option for 654 shares at an exercise price of
CGON filed a notice of proposed sale of restricted or control securities. The filing covers the planned sale of 13,109 common shares, with an aggregate market value of $549,660.37, through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 01/09/2026. The issuer had 80,666,179 common shares outstanding. The shares to be sold were acquired on 01/09/2026 by exercising stock options granted by the issuer, paid for in cash on the same date.
CG Oncology reported new clinical timing and data for its bladder cancer programs. The company now expects topline Phase 3 PIVOT-006 data in the first half of 2026 for intermediate-risk non–muscle invasive bladder cancer, a U.S. population estimated at over 50,000 patients. Updated BOND-003 Cohort P results for cretostimogene monotherapy in BCG-unresponsive papillary-only disease showed Kaplan-Meier high-grade event-free survival of 95.7%, 84.6% and 80.4% at 3, 6 and 9 months in 51 evaluable patients, with no Grade 3 or higher treatment-related adverse events, no radical cystectomies and no progression to muscle-invasive disease. First results from CORE-008 Cohort A in high-risk, BCG-naïve patients with CIS showed an overall complete response rate of 83.7% (41 of 49), including 79.2% with the original administration and 88.0% with an optimized two-step administration, with mostly low-grade, bladder-localized adverse events and no related serious or Grade 3+ events.
CG Oncology, Inc. (CGON) disclosed a new stock option grant to a director. On 11/24/2025, the reporting person received a director stock option to purchase 20,889 shares of CG Oncology common stock at an exercise price of $43.56 per share. The option expires on 11/23/2035 if not exercised.
According to the vesting terms, 1/36th of the shares subject to the option vest monthly following November 24, 2025, as long as the director continues to provide service to the company through each vesting date. After this grant, the reporting person beneficially owns 20,889 derivative securities directly in the form of these stock options.
CG Oncology, Inc. (CGON) director Christina Rossi has filed an initial insider ownership report indicating that she currently beneficially owns no securities of the company. Both the non-derivative and derivative security tables show no holdings, and the explanation section explicitly states that no securities are beneficially owned.